Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men.
Reginster JY, Abadie E, Delmas P, Rizzoli R, Dere W, der Auwera P, Avouac B, Brandi ML, Daifotis A, Diez-Perez A, Calvo G, Johnell O, Kaufman JM, Kreutz G, Laslop A, Lekkerkerker F, Mitlak B, Nilsson P, Orloff J, Smillie M, Taylor A, Tsouderos Y, Ethgen D, Flamion B. Reginster JY, et al. Among authors: daifotis a. Osteoporos Int. 2006 Jan;17(1):1-7. doi: 10.1007/s00198-005-1984-3. Epub 2005 Aug 10. Osteoporos Int. 2006. PMID: 16091835
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG. Saag KG, et al. Among authors: daifotis ag. N Engl J Med. 1998 Jul 30;339(5):292-9. doi: 10.1056/NEJM199807303390502. N Engl J Med. 1998. PMID: 9682041 Free article. Clinical Trial.
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A. Adachi JD, et al. Among authors: daifotis a. Arthritis Rheum. 2001 Jan;44(1):202-11. doi: 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W. Arthritis Rheum. 2001. PMID: 11212161 Free article. Clinical Trial.
Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group.
Ravn P, Weiss SR, Rodriguez-Portales JA, McClung MR, Wasnich RD, Gilchrist NL, Sambrook P, Fogelman I, Krupa D, Yates AJ, Daifotis A, Fuleihan GE. Ravn P, et al. Among authors: daifotis a. J Clin Endocrinol Metab. 2000 Apr;85(4):1492-7. doi: 10.1210/jcem.85.4.6549. J Clin Endocrinol Metab. 2000. PMID: 10770187 Clinical Trial.
Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group.
McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan G el-H, Reda C, Yates AJ, Ravn P. McClung M, et al. Among authors: daifotis a. Ann Intern Med. 1998 Feb 15;128(4):253-61. doi: 10.7326/0003-4819-128-4-199802150-00001. Ann Intern Med. 1998. PMID: 9471927 Clinical Trial.
28 results